Bacopa monnieri / Ca+2 Cancer Research Results

BM, Bacopa monnieri: Click to Expand ⟱

Features:

Bacopa monnieri — a medicinal botanical herb, also called Brahmi, typically used as a standardized oral extract enriched in bacosides, which are dammarane-type triterpenoid saponins. Its formal classification is a phytotherapeutic botanical / dietary supplement rather than an approved anticancer drug. Standard abbreviation: BM. The source is the aerial herb of Bacopa monnieri, a traditional Ayurvedic plant. Mechanistically, BM is best supported as a neurocognitive and cytoprotective adaptogenic extract; its anticancer activity is real but remains preclinical, heterogeneous, and often driven by isolated fractions or bacopasides rather than routine oral human exposure.

Primary mechanisms (ranked):

Modulation of intrinsic apoptosis and cell-cycle arrest in cancer models
Aquaporin-1 linked antitumor effects of bacopaside fractions, including reduced proliferation, migration, and angiogenic behavior
Anti-inflammatory signaling with suppression of NF-κB-linked survival programs
Context-dependent modulation of PI3K/AKT and MAPK stress-survival signaling
Redox modulation: antioxidant / NRF2-linked cytoprotection in normal tissues, but possible pro-apoptotic oxidative stress at higher in-vitro tumor doses

Bioavailability / PK relevance: Oral BM extracts are usually standardized to bacosides, but bacosides have limited aqueous solubility and modest systemic exposure; in-vivo metabolism to aglycones / downstream metabolites likely matters. This creates a delivery constraint for oncology because many direct tumor effects are reported at micromolar in-vitro concentrations or with enriched fractions not clearly achievable after routine oral supplementation.

In-vitro vs systemic exposure relevance: Common anticancer in-vitro concentrations likely exceed typical oral systemic exposure. By contrast, cognition-related effects appear compatible with chronic low-level oral exposure and adaptive signaling over weeks rather than acute high plasma peaks.

Clinical evidence status: Small human RCT evidence exists for cognition / stress-related outcomes. Dementia / AD evidence remains inconclusive and low-certainty. Oncology evidence is preclinical only; there is no established clinical anticancer role.

Key Active Compounds
  Bacosides (especially bacoside A and B)
  Brahmin
  Hersaponin
  Betulinic acid
  Steroidal saponins

AD Pathways:
  ↓ Aβ accumulation
  ↓ Tau hyperphosphorylation
  ↓ Pro-inflammatory cytokines (e.g., IL-1β, TNF-α, IL-6)
  ↑ Acetylcholine levels	Inhibits AChE,
  Strong antioxidant activity	↓ ROS, ↑ SOD, ↑ catalase, and ↑ GSH levels.

Potential Anticancer Mechanisms
  Reduces oxidative stress
  Inhibits NF-κB and COX-2
  Anti-angiogenic

whole-extract Bacopa monnieri effects from purified bacopaside I / II mechanisms; this distinction matters because the more specific anticancer mechanisms are often fraction-specific.

Bacopa monnieri mechanistic pathway map

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Intrinsic apoptosis and cell-cycle control	↑ apoptosis; ↓ proliferation; G0/G1 or G2/M arrest (model-dependent)	↔ / cytoprotective	R/G	Tumor growth restraint	Most reproducible cancer-facing effect across BM fractions and bacopasides; strength depends strongly on extract composition and concentration.
2	Aquaporin-1 axis	↓ proliferation; ↓ migration; ↓ invasion / angiogenic behavior	↔	R/G	Membrane transport-linked antitumor effect	This is one of the more specific mechanistic signals for bacopaside I / II, especially in colorectal and endothelial models; relevance is fraction-specific rather than clearly whole-extract universal.
3	NF-κB inflammatory survival signaling	↓	↓	R/G	Anti-inflammatory and anti-survival shift	Likely contributes more confidently to normal-tissue neuroprotection than to a clinically useful direct anticancer effect.
4	PI3K/AKT and MAPK stress-survival signaling	↓ AKT; ERK/JNK/p38 modulation (context-dependent)	↔ / adaptive	R/G	Reduced survival signaling	Reported in several models, but not yet a defining or standardized BM hallmark across tumor systems.
5	Mitochondrial ROS increase and apoptotic stress	↑ ROS (high concentration only); ↑ mitochondrial apoptosis	↓ oxidative injury	P/R	Redox bifurcation	Important duality: normal tissues trend antioxidant, while some tumor models show pro-apoptotic oxidative stress only at higher exposures.
6	NRF2-linked antioxidant defense	↔ / ↑ (context-dependent)	↑	R/G	Cytoprotection	Central for neuroprotection and normal-cell antioxidant effects; in cancer this could be neutral or potentially counter-therapeutic depending on context, so it is not ranked as a core anticancer mechanism.
7	Angiogenesis and endothelial remodeling	↓	↔	G	Reduced vascular support	Evidence is tied mainly to AQP1-active bacopaside work and endothelial assays rather than robust human translational data.
8	HIF-1α hypoxia adaptation	↓ (model-dependent)	↔	G	Reduced hypoxic adaptation	Secondary / contextual axis with limited direct evidence compared with apoptosis and AQP1-linked effects.
9	Chemosensitization or radiosensitization	↔ (insufficient evidence)	↔	G	Not established	No convincing clinical translation yet for use as a cancer sensitizer.
10	Clinical Translation Constraint	↓	↓	—	Exposure and standardization limitation	Main constraints are extract heterogeneity, fraction-specific mechanisms, uncertain human tumor exposure, and lack of oncology trials.

TSF legend: P: 0–30 min
R: 30 min–3 hr
G: >3 hr

Bacopa monnieri (BM; Brahmi) — standardized extracts (typically 20–55% bacosides) studied in cognitive aging, MCI, and stress-related impairment. Mechanistically a neuroprotective adaptogen with antioxidant, anti-inflammatory, and synaptic plasticity–modulating effects.

Primary mechanisms (conceptual rank):
1) ↓ Oxidative stress (↑ NRF2-linked antioxidant enzymes; ↓ lipid peroxidation)
2) ↓ Neuroinflammation (↓ NF-κB; ↓ TNF-α / IL-1β in models)
3) ↑ Synaptic plasticity signaling (↑ BDNF/CREB; dendritic spine density in models)
4) ↓ Aβ aggregation / toxicity (preclinical emphasis)
5) Cholinergic modulation (↑ acetylcholine tone; acetylcholinesterase modulation)

Bioavailability / PK relevance: Orally bioavailable extracts cross the BBB at low concentrations; chronic dosing appears necessary for measurable cognitive benefit (weeks). Plasma levels modest; effects likely cumulative/adaptive rather than acute pharmacologic spikes.

Clinical evidence status: Multiple small RCTs show modest improvements in memory acquisition and processing speed in older adults and MCI; not disease-modifying approval for AD.

Bacopa monnieri — AD / Neurodegeneration Pathway Map

Rank	Pathway / Axis	Cells	TSF	Primary Effect	Notes / Interpretation
1	ROS / Oxidative stress	↓	P/R	Reduced neuronal oxidative burden	Consistent antioxidant activity; decreases lipid peroxidation and improves endogenous antioxidant enzyme activity.
2	NRF2 axis	↑	R/G	Stress-defense gene upregulation	Supports increased SOD, catalase, glutathione enzymes; central to neuroprotection.
3	Neuroinflammation (NF-κB, cytokines)	↓	R/G	Reduced microglial inflammatory signaling	Important in slowing neurodegenerative progression in models.
4	BDNF / CREB signaling	↑	G	Synaptic plasticity enhancement	Linked to improved memory acquisition in animal and human cognitive studies.
5	Aβ aggregation / toxicity	↓ (preclinical)	G	Reduced amyloid-associated damage	Shown in animal and cell models; human biomarker confirmation limited.
6	Cholinergic signaling	↑ tone (context-dependent)	R/G	Improved neurotransmission	Modest acetylcholinesterase modulation and increased acetylcholine availability reported.
7	Mitochondrial function	↑	R/G	Improved bioenergetic resilience	Often secondary to reduced ROS and inflammation.
8	Ca²⁺ homeostasis	↔ / stabilized	P/R	Excitotoxic buffering	Indirect stabilization through antioxidant and mitochondrial support.
9	Clinical Translation Constraint	↓ (constraint)	—	Modest effect size	Benefits typically require ≥8–12 weeks; magnitude modest; not disease-modifying therapy.

TSF legend:
P: 0–30 min (direct antioxidant interactions)
R: 30 min–3 hr (acute signaling modulation)
G: >3 hr (gene regulation, synaptic adaptation)

Ca+2, Calcium Ion Ca+2: Click to Expand ⟱

Source:

Type:

In all eukaryotic cells, intracellular Ca2+ levels are maintained at low resting concentrations (approximately 100 nM) by the activity of the major Ca2+ extrusion system, the plasma membrane Ca2+-ATPase (PMCA), which exchanges extracellular protons (H+) for cytosolic Ca2+.
Indeed, sustained elevation of [Ca2+]C in the form of overload, saturating all Ca2+-dependent effectors, prolonged decrease in [Ca2+]ER, causing ER stress response, and high [Ca2+]M, inducing mitochondrial permeability transition (MPT), are considered to be pro-death factors.
In cancer the Ca2+-handling toolkit undergoes profound remodelling (figure 1) to favour activation of Ca2+-dependent transcription factors, such as the nuclear factor of activated T cells (NFAT), c-Myc, c-Jun, c-Fos that promote hypertrophic growth via induction of the expression of the G1 and G1/S phase transition cyclins (D and E) and associated cyclin-dependent kinases (CDK4 and CDK2).
Thus, cancer cells may evade apoptosis through decreasing calcium influx into the cytoplasm. This can be achieved by either downregulation of the expression of plasma membrane Ca2+-permeable ion channels or by reducing the effectiveness of the signalling pathways that activate these channels. Such protective measures would largely diminish the possibility of Ca2+ overload in response to pro-apoptotic stimuli, thereby impairing the effectiveness of mitochondrial and cytoplasmic apoptotic pathways.
Voltage-Gated Calcium Channels (VGCCs): Overexpression of VGCCs has been associated with increased tumor growth and metastasis in various cancers, including breast and prostate cancer.
Store-Operated Calcium Entry (SOCE): SOCE mechanisms, such as STIM1 and ORAI1, are often upregulated in cancer cells, contributing to enhanced cell survival and proliferation.
High intracellular calcium levels are associated with increased cell proliferation and migration, leading to a poorer prognosis. Calcium signaling can also influence hormone receptor status, affecting treatment responses.
Increased Ca²⁺ signaling is associated with advanced disease and metastasis. Patients with higher CaSR expression may have a worse prognosis due to enhanced tumor growth and resistance to apoptosis. -Ca2+ is an important regulator of the electric charge distribution of bio-membranes.

Scientific Papers found: Click to Expand⟱

5476-

BM,

In Vitro Synergistic Inhibition of HT-29 Proliferation and 2H-11 and HUVEC Tubulogenesis by Bacopaside I and II Is Associated with Ca2+ Flux and Loss of Plasma Membrane Integrity

vitro+vivo,

CRC,

HT29

TumCD↑, TumCMig↓, Ca+2↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Cell Death ⓘ

TumCD↑, 1,

Migration ⓘ

Ca+2↑, 1, TumCMig↓, 1,
Total Targets: 3

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: Ca+2, Calcium Ion Ca+2

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:339  Target#:38  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid